SMAD2 and cardiac hypertrophy: However, Sirt2-KO markedly exaggerated cardiac hypertrophy and fibrosis as well as decreases in cardiac ejection fraction and fractional shortening in aged (24-month-old) mice and Ang II-infused mice, which suggests a contradiction with the fact that SIRT2 helps SMAD2/3 activation [44].